138 related articles for article (PubMed ID: 36193305)
1. Preliminary Evaluation of Artificial Intelligence-Based Anti-Hepatocellular Carcinoma Molecular Target Study in Hepatocellular Carcinoma Diagnosis Research.
Wang Y; Wei C; Deng X; Gao S; Chen J
Biomed Res Int; 2022; 2022():8365565. PubMed ID: 36193305
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer.
Hong SH; Eun JW; Choi SK; Shen Q; Choi WS; Han JW; Nam SW; You JS
Oncotarget; 2016 May; 7(22):32628-40. PubMed ID: 27081696
[TBL] [Abstract][Full Text] [Related]
3. microRNA-608 inhibits human hepatocellular carcinoma cell proliferation via targeting the BET family protein BRD4.
He L; Meng D; Zhang SH; Zhang Y; Deng Z; Kong LB
Biochem Biophys Res Commun; 2018 Jul; 501(4):1060-1067. PubMed ID: 29777702
[TBL] [Abstract][Full Text] [Related]
4. BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage.
He DD; Shang XY; Wang N; Wang GX; He KY; Wang L; Han ZG
Oncogene; 2022 Mar; 41(10):1397-1409. PubMed ID: 35017665
[TBL] [Abstract][Full Text] [Related]
5. BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma.
Zhang P; Dong Z; Cai J; Zhang C; Shen Z; Ke A; Gao D; Fan J; Shi G
Int J Immunopathol Pharmacol; 2015 Mar; 28(1):36-44. PubMed ID: 25816404
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of miR-329 promotes cell invasion by regulating BRD4 and predicts poor prognosis in hepatocellular carcinoma.
Zhou J; Li W; Guo J; Li G; Chen F; Zhou J
Tumour Biol; 2016 Mar; 37(3):3561-9. PubMed ID: 26456956
[TBL] [Abstract][Full Text] [Related]
7. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
[TBL] [Abstract][Full Text] [Related]
8. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
9. Impact of bromodomain-containing protein 4 (BRD4) and intestine-specific homeobox (ISX) expression on the prognosis of patients with hepatocellular carcinoma' for better clarity.
Chuang KT; Wang SN; Hsu SH; Wang LT
Cancer Med; 2021 Aug; 10(16):5545-5556. PubMed ID: 34173348
[TBL] [Abstract][Full Text] [Related]
10. PES1 is transcriptionally regulated by BRD4 and promotes cell proliferation and glycolysis in hepatocellular carcinoma.
Fan P; Wang B; Meng Z; Zhao J; Jin X
Int J Biochem Cell Biol; 2018 Nov; 104():1-8. PubMed ID: 30172011
[TBL] [Abstract][Full Text] [Related]
11. Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma.
Yousef EH; El-Mesery ME; Habeeb MR; Eissa LA
Tumour Biol; 2020 Apr; 42(4):1010428320914475. PubMed ID: 32252611
[TBL] [Abstract][Full Text] [Related]
12. Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma.
Tsang FH; Law CT; Tang TC; Cheng CL; Chin DW; Tam WV; Wei L; Wong CC; Ng IO; Wong CM
Hepatology; 2019 Jun; 69(6):2502-2517. PubMed ID: 30723918
[TBL] [Abstract][Full Text] [Related]
13. Five Novel Oncogenic Signatures Could Be Utilized as AFP-Related Diagnostic Biomarkers for Hepatocellular Carcinoma Based on Next-Generation Sequencing.
Yu Z; Wang R; Chen F; Wang J; Huang X
Dig Dis Sci; 2018 Apr; 63(4):945-957. PubMed ID: 29442275
[TBL] [Abstract][Full Text] [Related]
14. Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma.
Wang JX; Zhang B; Yu JK; Liu J; Yang MQ; Zheng S
Chin Med J (Engl); 2005 Aug; 118(15):1278-84. PubMed ID: 16117882
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.
Hung MH; Chen YL; Chu PY; Shih CT; Yu HC; Tai WT; Shiau CW; Chen KF
Oncogene; 2016 Sep; 35(37):4891-902. PubMed ID: 26876205
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide-induced upregulation of miR-1294 suppresses tumor growth in hepatocellular carcinoma by targeting TEAD1 and PIM1.
Cai X; Yu L; Chen Z; Ye F; Ren Z; Jin P
Cancer Biomark; 2020; 28(2):221-230. PubMed ID: 32280078
[TBL] [Abstract][Full Text] [Related]
17. Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets.
Situ Y; Liang Q; Zeng Z; Chen J; Shao Z; Xu Q; Lu X; Cui Y; Zhang J; Lu L; Deng L
Front Endocrinol (Lausanne); 2023; 14():1089531. PubMed ID: 36793283
[TBL] [Abstract][Full Text] [Related]
18. An efficient model for auxiliary diagnosis of hepatocellular carcinoma based on gene expression programming.
Zhang L; Chen J; Gao C; Liu C; Xu K
Med Biol Eng Comput; 2018 Oct; 56(10):1771-1779. PubMed ID: 29546505
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
[TBL] [Abstract][Full Text] [Related]
20. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
